© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 1, 17-25,
January 2, 2002
© 2002 Oxford University Press
ARTICLE |
Matrix Metalloproteinase Activity, Bone Matrix Turnover, and Tumor Cell Proliferation in Prostate Cancer Bone Metastasis
Affiliations of authors: J. A. Nemeth, R. Yousif, M. Herzog, J. Upadhyay, B. Shekarriz, S. Bhagat, C. Mullins, Department of Urology, Wayne State University School of Medicine, Detroit, MI; M. Che, R. Fridman, Department of Pathology, Wayne State University School of Medicine, and The Barbara Ann Karmanos Cancer Institute, Detroit; M. L. Cher, Departments of Urology and Pathology, Wayne State University School of Medicine, and The Barbara Ann Karmanos Cancer Institute.
Correspondence to: Michael L. Cher, M.D., Departments of Urology and Pathology, Wayne State University School of Medicine, 540 E. Canfield, Rm. 9105, Detroit, MI 48201 (e-mail: mcher{at}med.wayne.edu).
Background: The metastasis of prostate cancer to bone is associated with a substantial increase in bone matrix turnover. Matrix metalloproteinases (MMPs) play roles in both normal bone remodeling and invasion and metastasis of prostate cancer. This study was designed to determine the role of MMP activity in prostate cancer that has metastasized to bone. Methods: Single human fetal bone fragments were implanted subcutaneously in immunodeficient mice. Four weeks later, PC3 human prostate cancer cells were injected directly into some of the implants, and daily treatment was begun with batimastat (a broad-spectrum MMP inhibitor). There were six mice (i.e., six implants) in each of four experimental arms: bone alone with and without batimastat and bone injected with PC3 cells with and without batimastat. Bone implants were harvested after 14 days of treatment and analyzed for MMP expression, bone histomorphometry, osteoclast counts, blood vessel density, and tumor cell proliferation and apoptosis. Complementary data were obtained from bone biopsy samples from patients and a bone organ coculture system. All statistical tests were two-sided. Results: MMPs were detected in tumor and stromal cells of clinical specimens and experimental bone implants. In vivo, MMP inhibition reduced the number of osteoclasts per millimeter in PC3-injected implants—from 8.2 (95% confidence interval [CI] = 7.9 to 8.5) to 3.0 (95% CI = 2.3 to 3.7) (P = .006). In addition, it prevented degradation of marrow trabeculae within the bone implants (cross-sectional area of implant occupied by mineralized trabeculae: untreated implant = 29.1% [95% CI = 27.1% to 31.1%], PC3-injected implant = 14.0% [95% CI = 10.9% to 17.1%] [P = .005 versus untreated], and batimastat-treated PC3-injected implant = 27.2% [95% CI = 22.4% to 32.0%] [P = .03 versus PC3 injected alone]). MMP inhibition reduced proliferating tumor cells from 20.8% (95% CI = 19.9% to 21.7%) to 7.4% (95% CI = 5.2% to 9.6%) (P = .006), without affecting angiogenesis or apoptosis. In vitro, MMP inhibition had no toxic effect on PC3 cells but prevented calcium release from bone fragments cocultured with PC3 cells. Conclusions: MMP activity appears to play an important role in bone matrix turnover when prostate cancer cells are present in bone. Bone matrix turnover and metastatic tumor growth appear to be involved in a mutually supportive cycle that is disrupted by MMP inhibition.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. J. Wilson, K. C. Nannuru, M. Futakuchi, A. Sadanandam, and R. K. Singh Cathepsin G Enhances Mammary Tumor-Induced Osteolysis by Generating Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand Cancer Res., July 15, 2008; 68(14): 5803 - 5811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Bonfil, Z. Dong, J. C. Trindade Filho, A. Sabbota, P. Osenkowski, S. Nabha, H. Yamamoto, S. R. Chinni, H. Zhao, S. Mobashery, et al. Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase: A Pivotal Role in Bone Response and Intraosseous Tumor Growth Am. J. Pathol., June 1, 2007; 170(6): 2100 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Banerjee, M. Hussain, Z. Wang, A. Saliganan, M. Che, D. Bonfil, M. Cher, and F. H. Sarkar In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer Cancer Res., April 15, 2007; 67(8): 3818 - 3826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Rahman, F. H. Sarkar, S. Banerjee, Z. Wang, D. J. Liao, X. Hong, and N. H. Sarkar Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol. Cancer Ther., November 1, 2006; 5(11): 2747 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Normanno and W. J Gullick Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr. Relat. Cancer, March 1, 2006; 13(1): 3 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Angelucci, G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. Muzi, A. Teti, C. Vicentini, and M. Bologna Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr. Relat. Cancer, March 1, 2006; 13(1): 197 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Lara Jr., W. M. Stadler, J. Longmate, D. I. Quinn, J. Wexler, M. Van Loan, P. Twardowski, P. H. Gumerlock, N. J. Vogelzang, E. E. Vokes, et al. A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases Clin. Cancer Res., March 1, 2006; 12(5): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Dong, R. D. Bonfil, S. Chinni, X. Deng, J. C. Trindade Filho, M. Bernardo, U. Vaishampayan, M. Che, B. F. Sloane, S. Sheng, et al. Matrix Metalloproteinase Activity and Osteoclasts in Experimental Prostate Cancer Bone Metastasis Tissue Am. J. Pathol., April 1, 2005; 166(4): 1173 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Valckenborgh, P. I. Croucher, H. De Raeve, C. Carron, E. De Leenheer, S. Blacher, L. Devy, A. Noel, E. De Bruyne, K. Asosingh, et al. Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma: A Study in the 5T2MM Mouse Model Am. J. Pathol., September 1, 2004; 165(3): 869 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Tester, M. Waltham, S.-J. Oh, S.-N. Bae, M. M. Bills, E. C. Walker, F. G. Kern, W. G. Stetler-Stevenson, M. E. Lippman, and E. W. Thompson Pro-Matrix Metalloproteinase-2 Transfection Increases Orthotopic Primary Growth and Experimental Metastasis of MDA-MB-231 Human Breast Cancer Cells in Nude Mice Cancer Res., January 15, 2004; 64(2): 652 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Cher, H. R. Biliran Jr., S. Bhagat, Y. Meng, M. Che, J. Lockett, J. Abrams, R. Fridman, M. Zachareas, and S. Sheng Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis PNAS, June 24, 2003; 100(13): 7847 - 7852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Fu, P. C. Smith, L. Zhang, M. A. Rubin, R. L. Dunn, Z. Yao, and E. T. Keller Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis J Natl Cancer Inst, June 18, 2003; 95(12): 878 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-G. Zhao, A.-Z. Xiao, R. G. Newcomer, H. I. Park, T. Kang, L. W. K. Chung, M. G. Swanson, H. E. Zhau, J. Kurhanewicz, and Q.-X. A. Sang Activation of Pro-gelatinase B by Endometase/Matrilysin-2 Promotes Invasion of Human Prostate Cancer Cells J. Biol. Chem., April 18, 2003; 278(17): 15056 - 15064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Weber and M. C. Gebhardt What's New in Musculoskeletal Oncology J. Bone Joint Surg. Am., March 31, 2003; 85(4): 761 - 767. [Full Text] [PDF]
|
|
|
|
|
|
E. Corey, L. G. Brown, J. E. Quinn, M. Poot, M. P. Roudier, C. S. Higano, and R. L. Vessella Zoledronic Acid Exhibits Inhibitory Effects on Osteoblastic and Osteolytic Metastases of Prostate Cancer Clin. Cancer Res., January 1, 2003; 9(1): 295 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Bissell, J. L. Beyec, and R. L. Anderson Prostate Cancer in Bone: Importance of Context for Inhibition of Matrix Metalloproteinases J Natl Cancer Inst, January 2, 2002; 94(1): 4 - 5. [Full Text] [PDF]
|
|